![]()
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screening for diabetes during and after an acute
myocardial infarction: when and how?
The incidence of hyperglycaemia during an ST elevation
myocardial infarction (STEMI) is significantly
high.1 Abnormal glucose tolerance during STEMI,
diagnosed on a glucose tolerance test (GTT), is an important predictor for
future cardiovascular outcomes.2 Though
previous studies have shown GTT to be reproducible a year after STEMI, this was
more based on numerical data than the actual patient
itself.3
In our study, all non-diabetic patients admitted with an
STEMI were subjected to 75 grams oral GTT on day 5 after index event to diagnose
abnormal glucose tolerance (AGT)[as diabetes (DM) and impaired glucose tolerance
(IGT)].4 Patients with AGT were referred back
to their family physicians for periodic monitoring and were prospectively called
back for a repeat GTT (Figure 1).
Seventy-nine consecutive patients were included for this
study and 27(34%) had abnormal glucose tolerance based on day 5 GTT. Two
patients were diagnosed with diabetes during the monitoring period with the
family physicians and were initiated on treatment. 25 (2 patients diagnosed with
DM during follow up period patients) had a repeat GTT done (mean 18 months;
range 9–26) which showed 9(36%) to have persistent AGT, effectively being
only 11% of the original cohort.
Our study again shows the high incidence of hyperglycaemia
immediately after a STEMI and the phenomenon of stress hyperglycaemia. This
study triggers a few vital issues: Firstly, HbA1c, in keeping with the current
recommendations (ADA guidelines) would be a much better investigation to
diagnose undiagnosed diabetes, as GTT does not differentiate between
pre-existing diabetes and incident stress hyperglycaemia; however a GTT would be
useful to guide immediate management.
Secondly, the link between AGT and future cardiovascular
outcomes after STEMI are based on admission plasma glucose and GTT rather than
HbA1c. Thirdly, GTT helps to diagnose more AGT compared to FPG alone (34% vs13%
on day 5 GTT, 41% vs. 22% on follow up GTT in our
study).5 However there is no clear consensus
about the exact timing of the first or follow up GTT after a STEMI.
With the emphasis on using HbA1c as a diagnostic test for
diabetes, clear guidelines are required regarding the most appropriate method
and timing of screening for diabetes and the role of GTT in patients with acute
myocardial infarction.
Figure 1. Flow diagram showing the results and
the protocol of the study
![]() Lakshminarayanan Varadhan
Specialty Registrar in Endocrinology and Diabetes University Hospitals of North Staffordshire NHS Trust Stoke on Trent, United Kingdom David Barton
Consultant Physician and Endocrinologist Princess Royal Hospital NHS Trust Telford, United Kingdom david.barton@sath.nhs.uk References:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current
issue | Search journal |
Archived issues | Classifieds
| Hotline (free ads) Subscribe | Contribute | Advertise | Contact Us | Copyright | Other Journals |